Skip to main content

Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Deliverables

training program oncology

D1.1 Report on training program oncology (M12)

training program business aspects

D1.2 Report on training program business aspects (M12)

Searching for OpenAIRE data...

Publications

Spores of <i>Clostridium</i> engineered for clinical efficacy and safety cause regression and cure of tumors <i>in vivo</i>

Author(s): John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton
Published in: Oncotarget, Issue 5/7, 2014, ISSN 1949-2553
DOI: 10.18632/oncotarget.1761

The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy

Author(s): Aleksandra M. Kubiak, Nigel P. Minton
Published in: Research in Microbiology, Issue 166/4, 2015, Page(s) 244-254, ISSN 0923-2508
DOI: 10.1016/j.resmic.2014.12.006

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress

Author(s): Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson
Published in: Cancers, Issue 8/7, 2016, Page(s) 63, ISSN 2072-6694
DOI: 10.3390/cancers8070063